iHub My Stocks Activity
Ticker Buzz Cloud
Most Followed Members
Data Tools >
Price & News Alerts
Markets in 3D
More Tools >
My Image Gallery
Personal Finance Q&A
Axsome Therapeutics (AXSM)
Add AXSM Price Alert
Search This Board:
5/22/2017 11:45:33 AM
- Board type:
- Posts Today:
Undiscovered and massive undervalued Biotech Stock with many Big News on the way . Axsome has 5 Phase 3 in various indication targeting very large Markets including Alzheimer and Depression .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .
This undiscovered Stock could be the next 10 bagger if only one of their 5 Phase 3 program is successful .GL
Market-Cap: $83 Million
Cash: $50.6 Million
(cash runway into the first quarter of 2019
Shares Out: 23 Million
New Presentation March 31
Anticipated Near-Term Clinical Milestones:
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
5x Phase 3 Programs in Pipeline :
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions in Phase 3
(SPA & Fast Track
7M patients in the U.S.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) in Phase 3
(Orphan+Fast Track Status)
No approved drug = high unmet need. 80,000 new cases per year in the U.S.
AXS-02 Chronic Low Back Pain Associated with Modic Changes in Phase 3 ---
1.6M patients in the U.S.
AXS-05 Agitation in patients with Alzheimer’s disease(AD) in Phase 2/3 ---
No approved medication = unmet medical need. 2M patients in the U.S.
AXS-05 STRIDE-1 Treatment resistant depression in Phase 3 ---
Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.
Herriott Tabuteau, MD
7 351 729
Fidelity Management & Research Co.
2 361 625
JPMorgan Asset Management (UK) Ltd.
1 432 456
Mark Coleman, MD
BlackRock Fund Advisors
Stifel Trust Co., NA
The Vanguard Group, Inc.
Lombard Odier Asset Management (USA) Corp.
JPMorgan Investment Management, Inc.
SSgA Funds Management, Inc.
the latest stock market analyst ratings:
Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.
Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.
Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.
Hey guys if you own shares of this low float stock then please put a high GTC sell order in to prevent your shares from being borrowed to short . This will help to drive this brutally undervalued stock much higher .Thank You
>>>>>>>>>>>>>>>>>>>>>How to Prevent your Shares Holdings from being Shorted<<<<<<<<<<<<<<<<<<<<<<
AXSM Detailed Quote
AXSM News: Quarterly Report (10-q)
05/09/2017 04:55:04 PM
AXSM News: Current Report Filing (8-k)
05/09/2017 04:32:28 PM
AXSM News: Axsome Therapeutics Reports First Quarter 2017 Financial Results
05/09/2017 07:00:00 AM
AXSM News: Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation
05/08/2017 07:00:00 AM
AXSM News: Proxy Statement (definitive) (def 14a)
04/28/2017 04:46:36 PM
Post New Msg
My Stocks (4)
another nice move and stock is still flying
05/22/17 11:45:33 AM
they didnt know this stock but this will
05/19/17 03:56:00 PM
Why don't more people follow this board or
05/19/17 03:34:05 PM
RALLLLLLLLLLLLLLLLLLLY i love it hehe
05/19/17 12:40:36 PM
and another buy rating with tgt $14
05/19/17 09:27:19 AM
look at the performance of the entire stock
05/17/17 11:58:05 PM
Any thoughts on the decline today?
05/17/17 08:13:12 PM
Another Guy likes AXSM ...more and more people
05/16/17 09:14:43 AM
Aegis Capital has reiterated a ‘Buy’ rating and
05/12/17 09:18:03 AM
AXSM ..Nice Article out by Napodano
05/09/17 12:56:33 PM
Yes, GREAT News, New Target is now????
05/08/17 11:06:16 AM
Fantastic News out today...
05/08/17 09:14:16 AM
Thinking to make an investment here. Thoughts?
05/07/17 01:26:12 PM
GREAT NEWS indeed
04/28/17 09:41:28 AM
LYTTON LAURENCE W has filed a new 13G,
04/27/17 03:17:00 PM
Need to break the MA(50) at $4.24 then
04/25/17 10:42:21 AM
Load up guys while its still heavily underpriced
04/20/17 12:22:18 PM
Bullish crossover in MACD and Stochastic oscillator.
04/13/17 11:53:01 AM
Bigger jump in share price coming once it
04/12/17 09:49:32 AM
I told a friend or 2 as well.
04/11/17 03:46:46 PM
looks like only a few people realize the
04/11/17 03:27:34 PM
Up she goes $5 coming guys
04/11/17 09:55:54 AM
looks like breakout is imminent
04/10/17 02:08:27 PM
this one will be over $10 before year
04/07/17 10:01:02 AM
Can somone summarize the conference. Out here in
04/05/17 09:24:04 AM
First Phase 3 results expected within 3-4 months
04/05/17 07:55:56 AM
Unless I read this incorrectly next news will
04/05/17 01:01:54 AM
Looks like tree shaking to steal more cheap
04/03/17 12:23:18 PM
Hopefully people get in before. IMO
03/31/17 12:19:48 PM
Axsome Therapeutics, Inc. at 16th Annual Needham Healthcare
03/31/17 10:52:02 AM
MarketCap $95M /Cash $50M /5x Phase 3 =
03/30/17 12:16:29 PM
looks like small consolidation before next leg up ..
03/30/17 10:15:48 AM
Share offering is finished ..$5 or higher is
03/29/17 09:38:33 AM
Would love to get a little pre conference
03/28/17 04:11:36 PM
$5+ before weekend likely especially with good news
03/28/17 03:44:17 PM
Hey guys if you own shares of this
03/28/17 11:52:56 AM
03/28/17 11:42:22 AM
here are the latest stock market analyst ratings:
03/28/17 10:34:19 AM
The Cheapest Biotech you can get in USA
03/27/17 11:48:35 AM
Rebound to $5+ coming ,stock is heavily oversold
03/23/17 10:00:21 AM
Post New Msg
My Stocks (4)
© 2017 InvestorsHub.Com, Inc.
Terms of Service
Advertise With Us
Stock Market 101
Investor Help Forum
Personal Finance Q&A
iHub on Facebook
iHub on Twitter
iHub iPhone/iPad App
iHub Android App
iHub BlackBerry App